Thymic enlargement in a patient with juvenile idiopathic arthritis during etanercept therapy

被引：0

作者：

Ismail Sari

Omer Binicier

Merih Birlik

Servet Akar

Erkan Yilmaz

Aydanur Kargi

Fatos Onen

Nurullah Akkoc

机构：

[1] Dokuz Eylul University School of Medicine,Department of Internal Medicine, Division of Rheumatology

[2] Dokuz Eylul University School of Medicine,Department of Radiology

[3] Dokuz Eylul University School of Medicine,Department of Pathology

[4] Dokuz Eylul Universitesi Tip Fakultesi Ic hastaliklari ABD Immunoloji-Romatoloji,undefined

来源：

Rheumatology International | 2009年 / 29卷

关键词：

Tumor necrosis factor alpha inhibitors; Adverse effects;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Tumor necrosis factor (TNF) alpha inhibitors are effective in the treatment of inflammatory rheumatic diseases. Despite their effectiveness, anti-TNF drugs have some drawbacks such as severe adverse effects including infections and possibly lymphoproliferative disorders. In this report we described a case of juvenile idiopathic arthritis patient who developed thymic enlargement (true thymic hyperplasia), mediastinal lymphadenopathy and pleurisy associated with systemic symptoms under Etanercept treatment. The clinical presentation was highly suggestive of malignancy and the patient underwent diagnostic mediastinoscopy with biopsy.

引用

共 50 条

[31] Development of Autoimmune Hepatitis in a Child With Systemic-Onset Juvenile Idiopathic Arthritis During Therapy With Etanercept
Fathalla, Basil M.
Goldsmith, Donald P.
Pascasio, Judy Mae C.
Baldridge, Alan
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2008, 14 (05) : 297 - 298
[32] Crohn's disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature
Wiegering, V.
Morbach, H.
Dick, A.
Girschick, H. J.
RHEUMATOLOGY INTERNATIONAL, 2010, 30 (06) : 801 - 804
[33] Crohn’s disease during etanercept therapy in juvenile idiopathic arthritis: a case report and review of the literature
V. Wiegering
H. Morbach
A. Dick
H. J. Girschick
Rheumatology International, 2010, 30 : 801 - 804
[34] Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
Alexeeva, Ekaterina
Dvoryakovskaya, Tatyana
Denisova, Rina
Sleptsova, Tatyana
Isaeva, Kseniya
Chomahidze, Alexandra
Fetisova, Anna
Mamutova, Anna
Alshevskaya, Alina
Gladkikh, Victor
Moskalev, Andrey
PEDIATRICS AND NEONATOLOGY, 2019, 60 (05): : 549 - 555
[35] Factors associated with failure of etanercept therapy in systemic onset juvenile idiopathic arthritis
Horneff, G
Girschick, H
Michels, H
Rogalski, B
Schmeling, H
ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S93 - S94
[36] Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis
ten Cate, R
van Suijlekom-Smit, LWA
Brinkman, DMC
Bekkering, WP
Jansen-van Wijngaarden, CJA
Vossen, JM
RHEUMATOLOGY, 2002, 41 (02) : 228 - 229
[37] Drug-survival and reasons for discontination of etanercept therapy in juvenile idiopathic arthritis
Horneff, G
Schmeling, H
Foeldvari, I
Ganser, G
Girschick, HJ
Hosbach, T
Huppertz, H
Keitzer, R
Kuester, RM
Michels, H
Moebius, D
Rogalski, B
Thon, A
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 383 - 384
[38] Effectiveness and compatibility of etanercept and methotrexate or etanercept for patients with juvenile idiopathic arthritis
De Bock, F.
Foeldvari, I.
Girschick, H. J.
Kuester, R.
Michels, H.
Moebius, D.
Schmeling, H.
Horneff, G.
ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 (07): : 628 - 629
[39] No benefit of the combination therapy etanercept and methotrexate compared to etanercept mono therapy in juvenile idiopathic arthritis – a matched pair analysis
Heinrike Schmeling
Gerd Horneff
Pediatric Rheumatology, 10 (Suppl 1)
[40] Nodulosis during etanercept therapy in patient with rheumatoid arthritis
Nandi, P.
Ma, M.
Johnson, D.
Hajela, V.
Yanni, G.
Kingsley, G.
RHEUMATOLOGY, 2008, 47 : II101 - II101

← 1 2 3 4 5 →